New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5428-

  Pasipanodya, Jotam ^a   Srivastava, Shashikant ^a   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATION; DRUG DISTRIBUTION; LETTER; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; OFLOXACIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84866342411     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00976-12     Document Type: Letter

References (5)

1. Angeby K, et al. 2011. Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:4492- 4493.
2. Chigutsa E, et al. 2012. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Antimicrob. Agents Chemother. 56:3857-3863.
3. Drusano GL, et al. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
4. Gumbo T. 2010. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob. Agents Chemother. 54:1484 -1491.
5. Williamson DA, et al. 2012. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 16:216 -220.